# Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.

> **NCT05024253** · PHASE3 · COMPLETED · sponsor: **Children's Cancer Hospital Egypt 57357** · enrollment: 48 (actual)

## Conditions studied

- Ewing Sarcoma of Bone
- Osteosarcoma

## Interventions

- **DRUG:** Tranexamic acid injection
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT05024253
- **Lead sponsor:** Children's Cancer Hospital Egypt 57357
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-02
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05024253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05024253, "Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05024253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*